Study Title: A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
 

• Open to Accrual at:
  • University of Illinois Cancer Center
  • Holden Comprehensive Cancer Center, University of Iowa
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 
• Learn more:
  • clinicaltrials.gov: NCT04699838

Study Contact: studies@hoosiercancer.org; (317) 921-2050.